{"id":"herombopag-csa","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Herombopag works by binding to and activating the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, thereby increasing platelet production. Cyclosporine A is added to suppress immune-mediated platelet destruction by inhibiting calcineurin-dependent T-cell activation. This combination approach addresses both the production and immune destruction pathways in thrombocytopenia.","oneSentence":"Herombopag is a thrombopoietin receptor agonist that stimulates platelet production, combined with cyclosporine A (CsA), an immunosuppressant that inhibits T-cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:47:41.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"}]},"trialDetails":[{"nctId":"NCT05660785","phase":"PHASE2","title":"Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-01","conditions":"Non Severe Aplastic Anemia, Untreated","enrollment":54},{"nctId":"NCT06695741","phase":"PHASE2","title":"Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-11-01","conditions":"Severe Aplastic Anemia, Cyclophosphamide Reduced-dose, Immunosuppressive Therapy","enrollment":75},{"nctId":"NCT05975996","phase":"PHASE2","title":"Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-07-10","conditions":"Severe Aplastic Anemia","enrollment":43},{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210},{"nctId":"NCT06004791","phase":"PHASE4","title":"A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Aplastic Anemia, Drug Effect","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["control"],"phase":"marketed","status":"active","brandName":"Herombopag + CsA","genericName":"Herombopag + CsA","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Herombopag is a thrombopoietin receptor agonist that stimulates platelet production, combined with cyclosporine A (CsA), an immunosuppressant that inhibits T-cell activation. Used for Immune thrombocytopenia (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}